ANGPTL3/8:一个目标,多种脂质疾病
1Center for Molecular Medicine and Genetics, Wayne State University Medical School, Detroit, MI 48202, USA.
Trends in molecular medicine
|October 30, 2025
概括
选择性阻断血管类蛋白 (ANGPTL) 3/8复合物有效降低甘油三和提高高密度胆固醇. 这种方法显示出作为各种失脂症的精密治疗方法的希望.
科学领域:
- 生物化学和分子生物学
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 血管蛋白样蛋白 (ANGPTL) 3/8 综合体是三甘油代谢的关键调节者.
- 脱脂症,以异常的脂质水平为特征,是心血管疾病的主要危险因素.
- 目前的治疗方法在解决复杂的脂质干扰方面存在局限性.
研究的目的:
- 评估选择性阻断ANGPTL3/8复合物的治疗潜力.
- 研究ANGPTL3/8对抗作用对甘油三和高密度胆固醇水平的影响.
- 探索ANGPTL3/8对抗性作为一种精确医学方法来治疗失脂症.
主要方法:
- 抑制ANGPTL3/8复合体的作用.
- 对脂质分区的评估.
- 分析与脱脂症相关的临床和遗传数据.
主要成果:
- 选择性阻断ANGPTL3/8复合物导致甘油三水平降低.
- 在ANGPTL3/8阻塞后,HDL胆固醇水平增加.
- 证据支持ANGPTL3/8对抗性对于混合性失脂血症和单一性高甘油三血症等疾病.
结论:
- ANGPTL3/8对抗性是一种有前途的治疗策略,用于失脂症.
- 这种方法通过纠正基本的脂质分区障碍来提供精确治疗.
- 进一步的研究支持其在遗传性和获得性脂质失调症中的应用.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Lipids as Anchors
7.1K
In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
7.1K
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311


